Inhibition of VEGFR and other tyrosine kinase receptors with pazopanib has been shown to improve PFS relative to placebo in patients with STS [5] and also alter signaling through PI3K/Akt and MAPK pathways [21,22]. Here, NTRK1 is linked to telomere syndrome.